HealthQuill Merck and Co. Inc.
US-based Merck Inc., two late-stage studies have met the main efficacy goal of suppressing the HIV-1 virus in adults receiving different antiretroviral therapies, according to a company statement.
Drugs Health Medical Pharma

Merck’s end-stage studies meet efficacy goal of suppressing HIV-1 virus

US-based Merck Inc., two late-stage studies have met the main efficacy goal of suppressing the HIV-1 virus in adults receiving different antiretroviral therapies,.

Read More
Modifi Biosciences, Inc., a Yale University spinout company formed in 2021, has been acquired by Merck & Co. for about $1.3 billion to gain access to therapies that aim to kill cancer cells by modifying cancer DNA selectively.
Drugs Health Pharma

Merck acquires Yale University spinout Modifi Biosciences for up to $1.3 billion

Modifi Biosciences, Inc., a Yale University spinout company formed in 2021, has been acquired by Merck & Co. for about $1.3 billion to.

Read More
Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of overall survival in patients previously treated for a type of metastatic colorectal cancer. 
Drugs Health Pharma

Merck’s trial drug combination for colorectal cancer fails main goal

Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of.

Read More
Daiichi Sankyo and Merck & Co., Inc. will initiate talks with global regulatory agencies after an end-stage trial of its drug for a form of lung cancer improved patients’ chances of extending survival without the disease progressing.
Drugs Health Pharma

Daiichi Sankyo-Merck’s trial lung cancer drug meets primary goal

Daiichi Sankyo and Merck & Co., Inc. will initiate talks with global regulatory agencies after an end-stage trial of its drug for a.

Read More
The US-based Merck and Co.’s investigational medicine to protect infants from respiratory syncytial virus (RSV) disease has resulted in lowering infections, according to the company.
Drugs Health Pharma

Merck’s experimental RSV injection lowers infections in infants 

The US-based Merck and Co.’s investigational medicine to protect infants from respiratory syncytial virus (RSV) disease has resulted in lowering infections, according to.

Read More